CASI | tickerfilter.com

Fundamental analysis

11%

Profitability 8%

Dept financing 5%

Liquidity 75%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

-68.45%

3 Months

-74.02%

6 Months

-89.58%

1 Year

-89.01%

2 Year

-94.75%

Key data

Stock price

$0.24

P/E Ratio

0.00

DAY RANGE

$0.21 - $0.32

EPS

-$0.41

52 WEEK RANGE

$0.21 - $3.09

52 WEEK CHANGE

-$88.54

MARKET CAP

101.888 M

YIELD

N/A

SHARES OUTSTANDING

15.461 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-13-2025

BETA

1.44

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

$682,228

Company detail

CEO: Wei-Wu He
Region: US
Website: casipharmaceuticals.com
Employees: 180
IPO year: 1996

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

CASI Pharmaceuticals, Inc. develops and commercializes therapeutics and pharmaceutical products. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-NHL)

CASI - CASI Pharmaceuticals, Inc (DE)